[{"address1": "15 Cushing", "city": "Irvine", "state": "CA", "zip": "92618", "country": "United States", "phone": "949 409 7600", "website": "https://www.oncocyte.com", "industry": "Diagnostics & Research", "sector": "Healthcare", "longBusinessSummary": "OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joshua  Riggs", "age": 40, "title": "President, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 504626, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Liu", "age": 27, "title": "Senior Director, Controller & Principal Accounting Officer", "yearBorn": 1996, "fiscalYear": 2023, "totalPay": 259832, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ekkehard  Schutz M.D., Ph.D.", "title": "Chief Science Officer", "fiscalYear": 2023, "totalPay": 409275, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea Susan James", "title": "Chief Financial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yuh-Min  Chiang Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter  Hong", "title": "VP, General Counsel & Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra  O'Donald", "title": "Senior Vice President of Business Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael D. West Ph.D.", "age": 70, "title": "Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.", "yearBorn": 1953, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.1, "open": 3.19, "dayLow": 3.05, "dayHigh": 3.19, "regularMarketPreviousClose": 3.1, "regularMarketOpen": 3.19, "regularMarketDayLow": 3.05, "regularMarketDayHigh": 3.19, "beta": 1.01, "forwardPE": -1.6666666, "volume": 2721, "regularMarketVolume": 2721, "averageVolume": 35540, "averageVolume10days": 7780, "averageDailyVolume10Day": 7780, "marketCap": 40773620, "fiftyTwoWeekLow": 2.08, "fiftyTwoWeekHigh": 4.34, "priceToSalesTrailing12Months": 39.85691, "fiftyDayAverage": 3.09086, "twoHundredDayAverage": 3.030585, "currency": "USD", "enterpriseValue": 37056156, "floatShares": 6027806, "sharesOutstanding": 13368400, "sharesShort": 203084, "sharesShortPriorMonth": 291341, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0152, "heldPercentInsiders": 0.12798001, "heldPercentInstitutions": 0.53683996, "shortRatio": 9.26, "shortPercentOfFloat": 0.0154, "bookValue": 1.698, "priceToBook": 1.7962309, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -36804000, "trailingEps": -4.28, "forwardEps": -1.83, "enterpriseToRevenue": 36.223, "enterpriseToEbitda": -1.832, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "OCX", "underlyingSymbol": "OCX", "shortName": "OncoCyte Corporation", "longName": "OncoCyte Corporation", "firstTradeDateEpochUtc": 1451485800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b57da45c-f76b-3b09-9f23-2fbd611aed8c", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.05, "targetHighPrice": 5.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.06, "targetMedianPrice": 4.13, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 9256000, "totalCashPerShare": 0.692, "ebitda": -20222000, "totalDebt": 3667000, "quickRatio": 1.298, "currentRatio": 1.385, "totalRevenue": 1023000, "debtToEquity": 16.152, "revenuePerShare": 0.109, "returnOnAssets": -0.16666001, "returnOnEquity": -1.01763, "freeCashflow": -5218500, "operatingCashflow": -18001000, "revenueGrowth": -0.775, "grossMargins": 0.30694, "operatingMargins": -54.45192, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]